Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 07, 2017 21:06 pm UTC| Business
SAN DIEGO, Nov. 07, 2017 -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2017 financial...
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update
Nov 07, 2017 21:06 pm UTC| Business
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1 million, provides...
HTG Molecular Diagnostics Reports 2017 Third Quarter Earnings
Nov 07, 2017 21:05 pm UTC| Business
Revenue increased 307% and 87%, respectively, compared to the three and nine month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz., Nov. 07, 2017 -- HTG...
Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference
Nov 07, 2017 21:06 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14,...
MINDBODY Announces Schedule of Upcoming Investor Conferences
Nov 07, 2017 21:05 pm UTC| Business
SAN LUIS OBISPO, Calif., Nov. 07, 2017 -- MINDBODY, Inc. (NASDAQ:MB), the leading technology platform for the wellness services industry, today announced that management will be attending the following investor...
Applied Optoelectronics Reports Third Quarter 2017 Results
Nov 07, 2017 21:04 pm UTC| Business
SUGAR LAND, Texas, Nov. 07, 2017 -- Applied Optoelectronics, Inc. (NASDAQ:AAOI), a leading provider of fiber-optic access network products for the internet datacenter, cable broadband, fiber-to-the-home (FTTH) and...
Editas Medicine Announces Third Quarter 2017 Results and Update
Nov 07, 2017 21:03 pm UTC| Business
CAMBRIDGE, Mass., Nov. 07, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2017, and provided an update on recent...
UK Inflation Stabilizes: November CPI at 2.6%, Signaling Economic Recovery
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update